Welcome to our dedicated page for Clearmind Medici SEC filings (Ticker: CMND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech filings rarely read like light bedtime material鈥攁nd Clearmind Medicine鈥檚 SEC disclosures are a case in point. Updates on MEAI trial cohorts, patent issuances across 19 families, and at-the-market financing terms are scattered through 200-page documents. If you have ever wondered, 鈥淗ow do I find Clearmind鈥檚 latest 10-K without digging for hours?鈥� or searched for 鈥淐learmind Medicine insider trading Form 4 transactions,鈥� this page is built for you.
Stock Titan鈥檚 AI breaks down each document the moment it hits EDGAR. Whether you open a Clearmind Medicine quarterly earnings report 10-Q filing, a sudden 8-K material event explained, or a Schedule 14A proxy statement on executive compensation, our engine highlights trial milestones, cash runway shifts, and warrant repricings in plain language. AG真人官方-time alerts flag Clearmind Medicine Form 4 insider transactions鈥攕o you can spot executive stock moves before the market digests them.
Inside each filing you will also find:
- Side-by-side revenue and R&D spend trends from successive reports for quick quarter-over-quarter comparisons
- Automatic extraction of newly granted patents protecting MEAI and other pipeline assets
- Contextual notes that translate complex risk-factor language into actionable insights
Stop downloading endless PDFs. From 鈥渦nderstanding Clearmind Medicine SEC documents with AI鈥� to tracking 鈥淐learmind Medicine executive stock transactions Form 4鈥� in real time, every regulatory detail is summarized so you can focus on decisions, not deciphering. Complex biotech filings, simplified.
Clearmind Medicine Inc. (NASDAQ: CMND) filed a Form 6-K for June 2025. The filing mainly furnishes a press release dated 27 June 2025 entitled 鈥淐learmind Medicine Expands Global Clinical Trial Targeting Multibillion-Dollar Alcohol Use Disorder Market.鈥�
Key points disclosed:
- The company is expanding its global clinical trial program aimed at Alcohol Use Disorder (AUD), a market the company characterises as multibillion-dollar.
- The first four paragraphs of the press release are automatically incorporated by reference into Clearmind鈥檚 effective shelf registration statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and its equity incentive Form S-8 (File No. 333-283695).
- No financial metrics, study data, or timelines are provided in the filing itself.
- The document is informational only; it does not request shareholder action nor announce financing.
The 6-K was signed by CEO Adi Zuloff-Shani on 27 June 2025.
Clearmind Medicine Inc. (CMND) has filed a Form 6-K for June 2025.
The filing mainly furnishes a press release dated 23 June 2025 entitled 鈥淐learmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder.鈥� No financial statements, earnings data, or transactional details accompany the report. The company simply notifies investors that the first two paragraphs of the press release are incorporated by reference into several existing U.S. registration statements on Forms F-3 (File Nos. 333-275991, 333-270859, 333-273293) and S-8 (File No. 333-283695).
The filing is signed by CEO Adi Zuloff-Shani on 23 June 2025. Aside from the clinical-site expansion disclosure, there are no other material events, financial metrics, or risk factors discussed.
FAQ
What is the current stock price of Clearmind Medici (CMND)?
What is the market cap of Clearmind Medici (CMND)?
